To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl2 in the daily clinical practice.
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 / Caffo, Orazio; Frantellizzi, Viviana; Tucci, Marcello; Galli, Luca; Monari, Fabio; Baldari, Sergio; Masini, Cristina; Bortolus, Roberto; Facchini, Gaetano; Alongi, Pierpaolo; Agostini, Stefania; Zichi, Clizia; Biasco, Elisa; Fanti, Stefano; Pignata, Salvatore; Filice, Angelina; Borsatti, Eugenio; Rossetti, Sabrina; Spada, Massimiliano; Cortesi, Enrico; De Vincentis, Giuseppe. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - (2020). [10.1007/s00259-020-04796-w]
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223
Frantellizzi, VivianaSecondo
;Cortesi, Enrico;De Vincentis, GiuseppeUltimo
2020
Abstract
To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl2 in the daily clinical practice.| File | Dimensione | Formato | |
|---|---|---|---|
|
Caffo_Fracture-risk_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
229.04 kB
Formato
Adobe PDF
|
229.04 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
